

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Yamamoto, et. al.

Examiner: NYA Group Art Unit: 3612

Serial No:

10/797,903

March 10, 2004

Filing Date: Priority Appln. No.: JP 2003-062823; filed: March 10, 2003

JP 2003-302803; filed: August 27, 2003

Title:

c-KIT KINASE INHIBITOR

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.D. Box 1450, Alexandría, VA 22313-1450

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate

TRANSMITTAL

In regard to the above-referenced patent application, enclosed please find the following:

- 1. Statement Filed Pursuant To The Duty Of Disclosure Under 37 CFR §§1.56, 1.97 and 1.98 (6 pp.);
- Form PTO-1449 (1 pg.); 2.
- Cited Art (1 references); 3.
- Statement of Limited Recognition Under 37 CFR § 10.9(b) (1 pg.); and 4.
- Return-Receipt Postcard. 5.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

CHOATE, HALL & STEWART

Dated: December Z, 2004

Charles E. Lyon, D.Phil.

Agent for Applicant

Limited Recognition Under 37 C.F.R. §10.9(b)

PATENT GROUP CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109

Tel: (617) 248-5000 Fax: (617) 248-4000

Page 1 of 1

Atty. Docket No.: 2003946-0080 Client Reference: FP04-0096-00US-XX



ATTORNEY DOCKET NO.: 2003946-0080 (FP04-0096-00US-XX)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Yamamoto, et. al.

Examiner:

NYA

Serial No.:

10/797,903

Art Unit:

3612

Filing Date:

March 10, 2004

Priority Appln. No.:

JP 2003-062823; filed: March 10, 2003

JP 2003-302803; filed: August 27, 2003

Title:

c-KIT KINASE INHIBITOR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- An original Information Disclosure Statement; or
- [X]A supplemental Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O./Box 1450, Alexandria, VA 22313-1450

Date

Signature

Sandra Saccocia

Typed or Printed Name of person signing certificate

U.S.S.N.: 10/797,903

3774552

Page 1 of 6

Atty. Docket No.: 2003946-0080

Client Reference No.: FP04-0096-00US-XX

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

[X]	Pursuant to 37 CFR § 1.97(b); no fee or certification is required:							
	[]	Within three months of the filing date of a national application other than						
		a cont	tinued prosecution application under § 1.53(d);					
	[]	Within three months of the date of entry of the national stage as set forth						
		in § 1.491 in an international application;						
	[X]	Before	Before the mailing of a first Office action on the merits; or					
	[]	Before the mailing of a first Office action after the filing of a request for						
		continued examination under § 1.114.						
[]	Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing							
	date of any of a final action under § 1.113, a notice of allowance under § 1.311, o							
	an action that otherwise closes prosecution in the application; Applicant hereby							
	either							
	[]	Certifies that either:						
		[]	Each item of information contained in the information disclosure					
			statement was first cited in any communication from a foreign					
			patent office in a counterpart foreign application not more than					
			three months prior to the filing of the information disclosure					
			statement: or					

Atty. Docket No.: 2003946-0080 Client Reference No.: FP04-0096-00US-XX U.S.S.N.: 10/797,903 Page 2 of 6

- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or Includes herewith the fee set forth in $\S 1.17(p)$.
- []
- Pursuant to 37 CFR § 1.97(d), after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby both:
 - [] Certifies that either:
 - [] Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the

U.S.S.N.: 10/797,903

Page 3 of 6 3774552 Client Reference No.: FP04-0096-00US-XX information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and

[] Includes herewith the fee set forth in $\S 1.17(p)$.

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

A copy of each cited reference not indicated with a † is included;

Copies of references indicated with a † on the attached form PTO-1449 are not included because the requirement to provide copies was waived pursuant to USPTO OG Notice of 8/5/03.

[] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the aboveidentified application:

Applicant certifies that the Information Disclosure Statement either:

[X]Does not contain non-English language citations;

[] Includes one or more translations of a non-English citation; or

[] Does contain non-English language citations, of which the following is a

concise explanation:

U.S.S.N.: 10/797,903 Page 4 of 6 Atty. Docket No.: 2003946-0080 Client Reference No.: FP04-0096-00US-XX

3774552

Remarks

The submission of this Information Disclosure Statement should not be construed as a

representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an

admission that the information cited in the statement is, or is considered to be, material to

patentability as defined in § 1.56(b).

The submission of this Information Disclosure Statement shall not be construed as a

representation that the information cited in the Statement is, or is considered to be, in fact, prior art

as defined by 35 USC § 102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other

information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited

patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office

during the examination of this application; and

3. The citations for the patent(s) and publication(s) be printed on any patent which

issues from this application.

U.S.S.N.: 10/797,903 Atty. Docket No.: 2003946-0080 Page 5 of 6 3774552 Client Reference No.: FP04-0096-00US-XX

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

CHOATE, HALL & STEWART

Charles E. Lyon, D.Phil.

Agent for Applicant

Limited Recognition Under 37 CFR § 10.9(b)

PATENT GROUP CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, Massachusetts 02109

Tel: (617) 248-5000 Fax: (617) 248-4000

Dated: December 2, 2004

U.S.S.N.: 10/797,903

3774552

Atty. Docket No.: 2003946-0080 Client Reference No.: FP04-0096-00US-XX



Form (REV. 8-83)	U.S. Departn Patent and Tr	Atty. Docket: 2003946-0080)	In re Application No. 10/797,903						
		Applicant: Yamamoto, et al.								
li ·	N DISCLOSURE STATI eral sheets if necessary)	Filing Date: March 10, 200)4	Group: 3612						
U.S. PATENT DOCUMENTS										
Examiner's Initials	U.S. Patent No.	Applicant	Issue Date		Class	Subclass				
U.S. PATENT APPLICATIONS										
Examiner's Initials:	Serial Number:	Applicant:	Filing Date:		Group:	Art Unit:				
FOREIGN PATENT DOCUMENTS										
Examiner's	Document No.	Country	Publication Date		Translation					
Initials					Yes	No				
OTHER DOCUMENTS										
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)									
/A.P./	Croom, et al., "Imatinib Mesylate", <i>Drugs</i> , 63(5): 513-522, 2003.									
EXAMINER	/Anna Pagonakis/	DATE CONSIDERED 12/05/2007								
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to										

applicant.